Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Liver Cirrhosis

  Free Subscription


Articles published in J Hepatol

Retrieve available abstracts of 200 articles:
HTML format
Text format



Single Articles


    November 2017
  1. LEE YH, Kim KJ, Yoo ME, Kim G, et al
    Association of nonalcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients.
    J Hepatol. 2017 Nov 23. pii: S0168-8278(17)32448.
    PubMed     Text format     Abstract available


  2. THULUVATH PJ, Kantsevoy S, Thuluvath AJ, Savva Y, et al
    Is Cryptogenic Cirrhosis Different from NASH Cirrhosis?
    J Hepatol. 2017 Nov 18. pii: S0168-8278(17)32441.
    PubMed     Text format     Abstract available


  3. INNES H, Barclay ST, Hayes PC, Fraser A, et al
    The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: role of the treatment regimen.
    J Hepatol. 2017 Nov 15. pii: S0168-8278(17)32429.
    PubMed     Text format     Abstract available


  4. TERZI E, Iavarone M, Pompili M, Veronese L, et al
    Contrast enhanced ultrasound identifies hepatocellular carcinoma in cirrhosis: a large multicenter retrospective study.
    J Hepatol. 2017 Nov 10. pii: S0168-8278(17)32428.
    PubMed     Text format     Abstract available


    October 2017
  5. D'AMICO G, Morabito A, D'Amico M, Pasta L, et al
    Clinical states of cirrhosis and competing risks.
    J Hepatol. 2017 Oct 27. pii: S0168-8278(17)32399.
    PubMed     Text format     Abstract available


  6. ALAVI M, Janjua NZ, Chong M, Grebely J, et al
    The contribution of alcohol-use disorder to decompensated cirrhosis among people with hepatitis C: an international study.
    J Hepatol. 2017 Oct 26. pii: S0168-8278(17)32398.
    PubMed     Text format     Abstract available


    September 2017
  7. THABUT D, Pauwels A, Carbonell N, Remy AJ, et al
    Cirrhotic patients with portal hypertension-related bleeding and an indication for early-TIPS: a large multicentre audit with real-life results.
    J Hepatol. 2017 Sep 13. pii: S0168-8278(17)32281.
    PubMed     Text format     Abstract available


  8. MOOKERJEE RP, Mehta G, Balasubramaniyan V, Mohamed FEZ, et al
    Corrigendum to "Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension" [J Hepatol 62 (2015) 325-331].
    J Hepatol. 2017 Sep 8. pii: S0168-8278(17)32209.
    PubMed     Text format    


  9. QI X, Liu F, Li Z, Chen S, et al
    Insufficient accuracy of computed tomography-based portal pressure assessment in hepatitis B virus-related cirrhosis.
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32277.
    PubMed     Text format    


  10. IRANMANESH P, Toso C
    Reply to the Letter to the Editor by Qi et al. entitled "Insufficient accuracy of computed tomography-based portal pressure assessment in hepatitis B virus-related cirrhosis".
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32274.
    PubMed     Text format    


  11. GROSSI G, Loglio A, Facchetti F, Borghi M, et al
    Tenofovir alafenamide as a Rescue Therapy in a Cirrhotic HBV Patient with a Hystory of Fanconi Syndrome and Multidrug Resistance: A Case Report.
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32260.
    PubMed     Text format     Abstract available


    August 2017
  12. SHARMA SA, Kowgier M, Hansen BE, Pieter Brouwer W, et al
    Toronto HCC Risk Index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis.
    J Hepatol. 2017 Aug 24. pii: S0168-8278(17)32248.
    PubMed     Text format     Abstract available


  13. MAJUMDAR A, Bailey M, Kemp WM, Bellomo R, et al
    Declining mortality in critically ill patients with cirrhosis in Australia and New Zealand between 2000 and 2015.
    J Hepatol. 2017 Aug 9. pii: S0168-8278(17)32198.
    PubMed     Text format     Abstract available


  14. THALHEIMER U, Giannelli V, Maimone S
    Non selective beta blockers in cirrhosis.
    J Hepatol. 2017 Aug 5. pii: S0168-8278(17)32194.
    PubMed     Text format    


  15. DEZSO K, Rokusz A, Bugyik E, Szucs A, et al
    Erratum to "Human liver regeneration in advanced cirrhosis is organized by the portal tree" [J Hepatol 66 (2017) 778-786].
    J Hepatol. 2017;67:430-436.
    PubMed     Text format    


    July 2017
  16. BERG T, Simon KG, Mauss S, Schott E, et al
    Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study.
    J Hepatol. 2017 Jul 20. pii: S0168-8278(17)32155.
    PubMed     Text format     Abstract available


  17. PIANO S, Tonon M, Vettore E, Stanco M, et al
    Incidence, predictors and outcomes of acute-on-chronic liver failure in outpatients with cirrhosis.
    J Hepatol. 2017 Jul 18. pii: S0168-8278(17)32151.
    PubMed     Text format     Abstract available


  18. ROBERTO C, Valeria R, Cristina N, Simona B, et al
    Gut-derived endotoxin stimulates factor viii secretion from endothelial cells. implications for hypercoagulability in cirrhosis.
    J Hepatol. 2017 Jul 14. pii: S0168-8278(17)32145.
    PubMed     Text format     Abstract available


  19. WEISS N, Colsch B, Fenaille F, Junot C, et al
    Metabolic signature for severe cirrhosis with inflammation or hepatic encephalopathy: do we really face two different entities?
    J Hepatol. 2017 Jul 5. pii: S0168-8278(17)32140.
    PubMed     Text format    


    June 2017
  20. XIANG X, You XM, Zhong JH, Li LQ, et al
    Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection.
    J Hepatol. 2017 Jun 21. pii: S0168-8278(17)32081.
    PubMed     Text format    


  21. POORDAD F, Nelson DR, Feld JJ, Fried MW, et al
    Safety of the 2D/3D direct acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - a pooled analysis.
    J Hepatol. 2017 Jun 20. pii: S0168-8278(17)32083.
    PubMed     Text format     Abstract available


  22. ARTRU F, Louvet A, Ruiz I, Levesque E, et al
    Liver transplantation in the most severely ill cirrhotic patients: a multicenter study in acute-on-chronic liver failure grade 3.
    J Hepatol. 2017 Jun 20. pii: S0168-8278(17)32079.
    PubMed     Text format     Abstract available


  23. CHAYANUPATKUL M, Kanwal F
    Author's reply to "Inappropriate use of FIB-4 index for cirrhosis detection in hepatocellular carcinoma patients".
    J Hepatol. 2017 Jun 18. pii: S0168-8278(17)32074.
    PubMed     Text format    


  24. CHAYANUPATKUL M, Kanwal F
    Author's reply to "Hepatocellular carcinoma (HCC) in the absence of cirrhosis in patients with chronic hepatitis B virus infection".
    J Hepatol. 2017 Jun 18. pii: S0168-8278(17)32075.
    PubMed     Text format    


  25. PANG Q, Liu HC, Zhou L, Jin H, et al
    Inappropriateuse of FIB-4 index for cirrhosis detection in hepatocellular carcinoma patients.
    J Hepatol. 2017 Jun 18. pii: S0168-8278(17)32082.
    PubMed     Text format    


  26. KALAMBOKIS GN, Baltayannis G, Christodoulou D, Christou L, et al
    Beta adrenergic blockade and advanced cirrhosis: does it really improve survival in patients with acute-on-chronic liver failure?
    J Hepatol. 2017 Jun 6. pii: S0168-8278(17)32064.
    PubMed     Text format    


    May 2017
  27. SHIN WJ, Hwang GS
    Reply to: "Pressure volume curves in cirrhosis: more than meets the eye".
    J Hepatol. 2017 May 9. pii: S0168-8278(17)32010.
    PubMed     Text format    


  28. RIPOLL C, Yotti R, Banares R, Bermejo J, et al
    Pressure Volume Curves in Cirrhosis: more than meets the eye.
    J Hepatol. 2017 May 8. pii: S0168-8278(17)32006.
    PubMed     Text format    


  29. MRIDHA AR, Wree A, Robertson AAB, Yeh MM, et al
    NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.
    J Hepatol. 2017;66:1037-1046.
    PubMed     Text format     Abstract available


    April 2017
  30. BRITO-AZEVEDO A
    Carvedilol and survival in cirrhosis with ascites: a cognitive bias?
    J Hepatol. 2017 Apr 20. pii: S0168-8278(17)30219.
    PubMed     Text format    


  31. BRUNO S, Maisonneuve P
    Response to the letter regarding the manuscript "Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population".
    J Hepatol. 2017 Apr 20. pii: S0168-8278(17)30216.
    PubMed     Text format    


  32. KWO PY, Poordad F, Asatryan A, Wang S, et al
    Glecaprevir and Pibrentasvir Yield High response Rates in Patients with HCV Genotype 1-6 without Cirrhosis.
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30211.
    PubMed     Text format     Abstract available


    February 2017
  33. SINHA R, Lockman KA, Mallawaarachchi N, Robertson M, et al
    Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites.
    J Hepatol. 2017 Feb 14. pii: S0168-8278(17)30073.
    PubMed     Text format     Abstract available


  34. CABIBBO G, Petta S, Barbara M, Attardo S, et al
    Hepatic Decompensation is the Major Driver of Death In HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma.
    J Hepatol. 2017 Feb 9. pii: S0168-8278(17)30070.
    PubMed     Text format     Abstract available


    January 2017
  35. BOURSIER J, de Ledinghen V, Leroy V, Anty R, et al
    A stepwise algorithm using a at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis.
    J Hepatol. 2017 Jan 11. pii: S0168-8278(17)30007.
    PubMed     Text format     Abstract available


    December 2016
  36. CRUZ-LEMINI M, Altamirano J, Ndugga N, Abraldes JG, et al
    Reply to: Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide: methodological issues of confounding and prediction models.
    J Hepatol. 2016 Dec 30. pii: S0168-8278(16)30756.
    PubMed     Text format    


  37. AYUBI E, Safiri S, Sani M, Khazaei S, et al
    Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide: methodological issues of confounding and prediction models.
    J Hepatol. 2016 Dec 30. pii: S0168-8278(16)30758.
    PubMed     Text format    


  38. WEISS E, Rautou PE, Fasseu M, Giabicani M, et al
    Type I interferon signaling in systemic immune cells from patients with alcoholic cirrhosis and its association with outcome.
    J Hepatol. 2016 Dec 28. pii: S0168-8278(16)30741.
    PubMed     Text format     Abstract available


  39. ARROYO V, Moreau R
    Diagnosis and prognosis of acute on chronic liver failure (ACLF) in cirrhosis.
    J Hepatol. 2016 Dec 15. pii: S0168-8278(16)30577.
    PubMed     Text format    


  40. MANGIA A, Susser S, Piazzolla V, Agostinacchio E, et al
    Sofosbuvir and Ribavirin for genotype 2 HCV infected patients with cirrhosis: a real life experience.
    J Hepatol. 2016 Dec 10. pii: S0168-8278(16)30707.
    PubMed     Text format     Abstract available


  41. MONTAGNESE S, De Rui M, Angeli P, Amodio P, et al
    Neuropsychiatric Performance in Patients with Cirrhosis: Who is "Normal"?
    J Hepatol. 2016 Dec 3. pii: S0168-8278(16)30698.
    PubMed     Text format     Abstract available


    November 2016
  42. DEZSO K, Rokusz A, Bugyik E, Szucs A, et al
    Human liver regeneration in advanced cirrhosis is organized by the portal tree.
    J Hepatol. 2016 Nov 29. pii: S0168-8278(16)30690.
    PubMed     Text format     Abstract available


  43. NOTARPAOLO A, Layese R, Magistri P, Gambato M, et al
    Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
    J Hepatol. 2016 Nov 26. pii: S0168-8278(16)30688.
    PubMed     Text format     Abstract available


  44. REIBERGER T, Mandorfer M
    Beta adrenergic blockade and decompensated cirrhosis.
    J Hepatol. 2016 Nov 15. pii: S0168-8278(16)30647.
    PubMed     Text format     Abstract available


    October 2016
  45. WANNHOFF A, Friedrich K, Gotthardt DN
    Reduced influence of procoagulant changes on survival in patients with advanced cirrhosis.
    J Hepatol. 2016 Oct 24. pii: S0168-8278(16)30583.
    PubMed     Text format    


  46. VAN DER MEER AJ, Feld JJ, Hofer H, Almasio PL, et al
    Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.
    J Hepatol. 2016 Oct 22. pii: S0168-8278(16)30582.
    PubMed     Text format     Abstract available


  47. POTZE W, Sanyal AJ, Lisman T
    How to assess hemostatic capacity in patients with cirrhosis?
    J Hepatol. 2016 Oct 18. pii: S0168-8278(16)30576.
    PubMed     Text format    


    September 2016
  48. CHAYANUPATKUL M, Omino R, Mittal S, Kramer JR, et al
    Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection.
    J Hepatol. 2016 Sep 28. pii: S0168-8278(16)30540.
    PubMed     Text format     Abstract available


  49. SHIN WJ, Song JG, Jun IG, Moon YJ, et al
    Effect of ventriculo-arterial coupling on transplant outcomes in cirrhotics: Analysis of pressure-volume curve relations.
    J Hepatol. 2016 Sep 26. pii: S0168-8278(16)30536.
    PubMed     Text format     Abstract available


    August 2016
  50. BRITO-AZEVEDO A, Perez RM, Moraes Coelho HS, Fernandes ES, et al
    The Anti-inflammatory Role of Propranolol in Cirrhosis: Preventing the Inflammatory Exhaustion?
    J Hepatol. 2016 Aug 16. pii: S0168-8278(16)30432.
    PubMed     Text format    


    July 2016
  51. CARDOSO H, Vale AM, Rodrigues S, Goncalves R, et al
    High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis.
    J Hepatol. 2016 Jul 28. pii: S0168-8278(16)30397.
    PubMed     Text format    


  52. SOLA E, Kerbert JC, Verspaget HW, Moreira R, et al
    Plasma copeptin as biomarker of disease progression and prognosis in cirrhosis.
    J Hepatol. 2016 Jul 12. pii: S0168-8278(16)30326.
    PubMed     Text format     Abstract available


  53. ALAVI M, Law MG, Grebely J, Amin J, et al
    Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: a population-based study, 1995-2012.
    J Hepatol. 2016 Jul 8. pii: S0168-8278(16)30321.
    PubMed     Text format     Abstract available


  54. STEIN E, Cruz-Lemini M, Altamirano J, Ndugga N, et al
    Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide.
    J Hepatol. 2016 Jul 5. pii: S0168-8278(16)30307.
    PubMed     Text format     Abstract available


  55. CHEUNG MC, Walker AJ, Hudson BE, Verma S, et al
    Outcomes after successful direct acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis.
    J Hepatol. 2016 Jul 4. pii: S0168-8278(16)30314.
    PubMed     Text format     Abstract available


  56. MAURICE J, Brodkin E, Arnold F, Navaratnam A, et al
    Validation of the Baveno Vi Criteria to Identify Low Risk Cirrhotic Patients not Requiring Endoscopic Surveillance for Varices.
    J Hepatol. 2016 Jul 4. pii: S0168-8278(16)30316.
    PubMed     Text format     Abstract available


    June 2016
  57. CONTI F, Buonfiglioli F, Scuteri A, Crespi C, et al
    Early Occurrence and Recurrence of Hepatocellular Carcinoma in HCV-related Cirrhosis Treated with Direct Acting Antivirals.
    J Hepatol. 2016 Jun 24. pii: S0168-8278(16)30303.
    PubMed     Text format     Abstract available


  58. KOZBIAL K, Moser S, Schwarzer R, Laferl H, et al
    Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with SVR following IFN-free DAA treatment.
    J Hepatol. 2016 Jun 15. pii: S0168-8278(16)30271.
    PubMed     Text format    


  59. DAVULURI G, Krokowski D, Guan BJ, Kumar A, et al
    Metabolic adaptation of skeletal muscle to hyperammonemia drives the beneficial effects of L-leucine in cirrhosis.
    J Hepatol. 2016 Jun 15. pii: S0168-8278(16)30266.
    PubMed     Text format     Abstract available


  60. RATZIU V, Marchesini G
    When the journey from obesity to cirrhosis takes an early start.
    J Hepatol. 2016 Jun 14. pii: S0168-8278(16)30207.
    PubMed     Text format    


  61. SINCLAIR M, Grossmann M, Hoermann R, Angus PW, et al
    Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: A randomised controlled trial.
    J Hepatol. 2016 Jun 13. pii: S0168-8278(16)30269.
    PubMed     Text format     Abstract available


  62. KALAMBOKIS GN, Oikonomou A, Christou L, Kolaitis NI, et al
    von Willebrand factor and procoagulant imbalance independently predict outcome in patients with cirrhosis and thrombocytopenia.
    J Hepatol. 2016 Jun 10. pii: S0168-8278(16)30262.
    PubMed     Text format     Abstract available


    May 2016
  63. NADIM MK, Durand F, Kellum JA, Levitsky J, et al
    Corrigendum to "Management of the critically ill patients with cirrhosis: A multidisciplinary perspective".
    J Hepatol. 2016 May 27. pii: S0168-8278(16)30185.
    PubMed     Text format    


  64. FRANCOZ C, Nadim MK, Durand F
    Kidney Biomarkers in Cirrhosis.
    J Hepatol. 2016 May 26. pii: S0168-8278(16)30211.
    PubMed     Text format     Abstract available


  65. OLESEN SS, Gram M, Jackson CD, Halliday E, et al
    Electroencephalogram variability in patients with cirrhosis associates with the presence and severity of hepatic encephalopathy.
    J Hepatol. 2016 May 13. pii: S0168-8278(16)30189.
    PubMed     Text format     Abstract available


  66. VANDENBULCKE H, Moreno C, Colle I, Knebel JF, et al
    Alcohol intake increases the risk of hepatocellular carcinoma in patients with hepatitis C virus-related compensated cirrhosis: a prospective study.
    J Hepatol. 2016 May 12. pii: S0168-8278(16)30184.
    PubMed     Text format     Abstract available


    April 2016
  67. FOSTER G
    Reply to: "High mortality during direct acting antiviral therapy for hepatitis C patients with Child's C cirrhosis: Results of the Irish Early Access Programme".
    J Hepatol. 2016 Apr 27. pii: S0168-8278(16)30142.
    PubMed     Text format    


  68. GRAY E, O'Leary A, Stewart S, Bergin C, et al
    High mortality during direct acting antiviral therapy for hepatitis C patients with Child's C cirrhosis: Results of the Irish Early Access Programme.
    J Hepatol. 2016 Apr 27. pii: S0168-8278(16)30143.
    PubMed     Text format    


  69. MARI M, Tutusaus A, Garcia de Frutos P, Morales A, et al
    Genetic and clinical data reinforce the role of GAS6 and TAM receptors in liver fibrosis.
    J Hepatol. 2016;64:983-4.
    PubMed     Text format    


  70. PETTA S, Marra F
    Reply to 'Genetic and clinical data reinforce the role of GAS6 and TAM receptors in liver fibrosis'.
    J Hepatol. 2016;64:984-5.
    PubMed     Text format    


  71. DUBUQUOY L
    Lipocalin 2 highlights the complex role of neutrophils in alcoholic liver disease.
    J Hepatol. 2016;64:770-2.
    PubMed     Text format    


  72. WESTBROOK RH, Dusheiko G, Williamson C
    Pregnancy and liver disease.
    J Hepatol. 2016;64:933-45.
    PubMed     Text format     Abstract available


    March 2016
  73. BRUNO S, Di Marco V, Iavarone M, Roffi L, et al
    Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population.
    J Hepatol. 2016 Mar 23. pii: S0168-8278(16)00075.
    PubMed     Text format     Abstract available


  74. ARIZA X, Graupera I, Coll M, Sola E, et al
    Neutrophil gelatinase-associated lipocalin is a biomarker of acute-on-chronic liver failure and prognosis in cirrhosis.
    J Hepatol. 2016 Mar 14. pii: S0168-8278(16)30029.
    PubMed     Text format     Abstract available


  75. CURRY MP
    DAA for decompensated cirrhosis. Efficacy and safety are now established.
    J Hepatol. 2016 Mar 3. pii: S0168-8278(16)30007.
    PubMed     Text format    


  76. PETTA S, Valenti L, Marra F, Grimaudo S, et al
    MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease.
    J Hepatol. 2016;64:682-90.
    PubMed     Text format     Abstract available


  77. MOOKERJEE RP, Pavesi M, Thomsen KL, Mehta G, et al
    Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure.
    J Hepatol. 2016;64:574-82.
    PubMed     Text format     Abstract available


    February 2016
  78. BUCSICS T, Schwabl P, Mandorfer M, Peck-Radosavljevic M, et al
    Prognosis of cirrhotic patients with fungiascites and spontaneous fungal peritonitis (SFP).
    J Hepatol. 2016 Feb 22. pii: S0168-8278(16)00155.
    PubMed     Text format    


  79. ALEXOPOULOU A, Vasilieva L, Agiasotelli D, Dourakis SP, et al
    Reply to "Prognosis of cirrhotic patients with fungiascites and spontaneous fungal peritonitis".
    J Hepatol. 2016 Feb 20. pii: S0168-8278(16)00121.
    PubMed     Text format    


  80. LOUVET A
    Restoration of bactericidal activity of neutrophils by myeloperoxidase release: a new perspective for preventing infection in alcoholic cirrhosis.
    J Hepatol. 2016 Feb 13. pii: S0168-8278(16)00125.
    PubMed     Text format    


  81. ESLAM M, Hashem AM, Romero-Gomez M, Berg T, et al
    FibroGENE: A gene-based model for staging liver fibrosis.
    J Hepatol. 2016;64:390-8.
    PubMed     Text format     Abstract available


    January 2016
  82. FOSTER GR, Irving WL, Cheung MC, Walker AJ, et al
    Cohort study of the impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis.
    J Hepatol. 2016 Jan 29. pii: S0168-8278(16)00065.
    PubMed     Text format     Abstract available


  83. TREBICKA J, von Heydebrand M, Lehmann J, Tofteng F, et al
    Assessment of beta-blocker response by expression of beta-Arrestin2 and RhoA/ROCK2 in antrum mucosa in cirrhotic patients.
    J Hepatol. 2016 Jan 28. pii: S0168-8278(16)00057.
    PubMed     Text format     Abstract available


  84. UDOMPAP P, Mannalithara A, Heo N, Kim D, et al
    Increasing Prevalence of Cirrhosis among US Adults Aware or Unaware of their Chronic Hepatitis C Virus Infection.
    J Hepatol. 2016 Jan 22. pii: S0168-8278(16)00014.
    PubMed     Text format     Abstract available


  85. LUA I, Li Y, Zagory JA, Wang KS, et al
    Characterization of hepatic stellate cells, portal fibroblasts, and mesothelial cells in normal and fibrotic livers.
    J Hepatol. 2016 Jan 19. pii: S0168-8278(16)00015.
    PubMed     Text format     Abstract available


  86. YANG YH, Chen WC, Tsai YH, Chen PC, et al
    Reply to "Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection".
    J Hepatol. 2016 Jan 18. pii: S0168-8278(16)00011.
    PubMed     Text format    


  87. MCPHAIL MJ, Shawcross DL, Lewis MR, Coltart I, et al
    Multivariate metabotyping of plasma accurately predicts survival in patients with decompensated cirrhosis.
    J Hepatol. 2016 Jan 18. pii: S0168-8278(16)00006.
    PubMed     Text format     Abstract available


  88. FIORE M, Leone S
    Use of anti-fungals in critically ill cirrhotic patients with spontaneous peritonitis.
    J Hepatol. 2016 Jan 18. pii: S0168-8278(16)00013.
    PubMed     Text format    


  89. YU ML
    Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection.
    J Hepatol. 2016 Jan 18. pii: S0168-8278(16)00012.
    PubMed     Text format    


  90. CASTERA L
    Non-invasive tests for liver fibrosis progression and regression.
    J Hepatol. 2016;64:232-3.
    PubMed     Text format    


  91. YOUNOSSI ZM, Stepanova M, Estep M, Negro F, et al
    Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin.
    J Hepatol. 2016;64:29-36.
    PubMed     Text format     Abstract available


  92. KARSDAL MA, Genovese F, Madsen EA, Manon-Jensen T, et al
    Collagen and tissue turnover as a function of age: Implications for fibrosis.
    J Hepatol. 2016;64:103-9.
    PubMed     Text format     Abstract available


  93. JIANG M, Klein M, Zanger UM, Mohammad MK, et al
    Inflammatory regulation of steroid sulfatase: A novel mechanism to control estrogen homeostasis and inflammation in chronic liver disease.
    J Hepatol. 2016;64:44-52.
    PubMed     Text format     Abstract available


    December 2015
  94. GARCIA-TSAO G
    Beta-Blockers in Cirrhosis: The Window Re-Opens.
    J Hepatol. 2015 Dec 24. pii: S0168-8278(15)00814.
    PubMed     Text format    


  95. UBEDA M, Lario M, Munoz L, Borrero MJ, et al
    Obeticholic acid reduces bacterial translocation, restores intestinal barrier and inhibits inflammation in cirrhotic rats.
    J Hepatol. 2015 Dec 23. pii: S0168-8278(15)00812.
    PubMed     Text format     Abstract available


  96. BOUSSIF A, Rolas L, Weiss E, Bouriche H, et al
    Impaired AKT/MAP-Kinase signaling, myeloperoxidase release and bactericidal activity of neutrophils from patients with alcoholic cirrhosis.
    J Hepatol. 2015 Dec 21. pii: S0168-8278(15)00806.
    PubMed     Text format     Abstract available


  97. CERINI F, Vilaseca M, Lafoz E, Garcia-Irigoyen O, et al
    Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats.
    J Hepatol. 2015 Dec 11. pii: S0168-8278(15)00804.
    PubMed     Text format     Abstract available


    November 2015
  98. KOOT BG, Alders M, Verheij J, Beuers UH, et al
    A de novo mutation in KCNN3 associated with autosomal dominant idiopathic non-cirrhotic portal hypertension.
    J Hepatol. 2015 Nov 30. pii: S0168-8278(15)00785.
    PubMed     Text format     Abstract available


  99. WELKER MW, Luhne S, Lange CM, Vermehren J, et al
    Lactic acidosis in patients with hepatitis C virus related cirrhosis and combined ribavirin/sofosbuvir treatment.
    J Hepatol. 2015 Nov 30. pii: S0168-8278(15)00792.
    PubMed     Text format     Abstract available


  100. GRONBAEK H, Rodgaard-Hansen S, Aagaard NK, Arroyo V, et al
    The soluble macrophage activation markers sCD163 and Mannose Receptor (sMR) predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF).
    J Hepatol. 2015 Nov 27. pii: S0168-8278(15)00779.
    PubMed     Text format     Abstract available


  101. PAGE A, Paoli P, Moran Salvador E, White S, et al
    Hepatic Stellate Cell Transdifferentiation Involves Genome-Wide Remodeling of the DNA Methylation Landscape.
    J Hepatol. 2015 Nov 26. pii: S0168-8278(15)00782.
    PubMed     Text format     Abstract available


  102. RAY KIM W, Berg T, Asselah T, Flisiak R, et al
    Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients.
    J Hepatol. 2015 Nov 25. pii: S0168-8278(15)00770.
    PubMed     Text format     Abstract available


  103. EGUCHI A, Jeu XM, Johnson CD, Nektaria A, et al
    Liver Bid-suppression for treatment of fibrosis associated with nonalcoholic steatohepatitis.
    J Hepatol. 2015 Nov 7. pii: S0168-8278(15)00732.
    PubMed     Text format     Abstract available


    October 2015
  104. NADIM MK, Durand F, Kellum JA, Levitsky J, et al
    Management of the Critically Ill Patient with Cirrhosis: A Multidisciplinary Perspective.
    J Hepatol. 2015 Oct 28. pii: S0168-8278(15)00718.
    PubMed     Text format    


  105. ORO D, Yudina T, Fernandez-Varo G, Casals E, et al
    Cerium oxide nanoparticles reduce steatosis, portal hypertension and display antiinflammatory properties in rats with liver fibrosis.
    J Hepatol. 2015 Oct 28. pii: S0168-8278(15)00719.
    PubMed     Text format     Abstract available


  106. FELD JJ, Moreno C, Trinh R, Tam E, et al
    Sustained Virologic Response of 100% in HCV Genotype 1b Patients with Cirrhosis Receiving Ombitasvir/Paritaprevir/r and Dasabuvir for 12 Weeks.
    J Hepatol. 2015 Oct 14. pii: S0168-8278(15)00676.
    PubMed     Text format     Abstract available


  107. CHUNG SI, Moon H, Ju HL, Cho KJ, et al
    Hepatic expression of Sonic Hedgehog induces liver fibrosis and promotes hepatocarcinogenesis in a transgenic mouse model.
    J Hepatol. 2015 Oct 12. pii: S0168-8278(15)00678.
    PubMed     Text format     Abstract available


    September 2015
  108. BEUERS U, Gershwin ME, Gish RG, Invernizzi P, et al
    Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'.
    J Hepatol. 2015 Sep 10. pii: S0168-8278(15)00459.
    PubMed     Text format    


  109. GALBOIS A, Maury E, Guidet B, Ait-Oufella H, et al
    Reply to: "Is skin mottling a predictor of high mortality in non-selected patients with cirrhosis admitted to intensive care unit?".
    J Hepatol. 2015;63:772-3.
    PubMed     Text format    


  110. CASSINOTTO C, de Ledinghen V
    Reply to: "New imaging assisted methods for liver fibrosis quantification: Is it really favorable to classical transient elastography?".
    J Hepatol. 2015;63:767.
    PubMed     Text format    


  111. LANTHIER N, Starkel P, Horsmans Y
    New imaging assisted methods for liver fibrosis quantification: Is it really favorable to classical transient elastography?
    J Hepatol. 2015;63:765-6.
    PubMed     Text format    


    August 2015
  112. MORATALLA A, Caparros E, Juanola O, Portune K, et al
    Bifidobacterium pseudocatenulatum CECT7765 induces an M2 anti-inflammatory transition in macrophages from patients with cirrhosis.
    J Hepatol. 2015 Aug 31. pii: S0168-8278(15)00592.
    PubMed     Text format     Abstract available


  113. BUREAU C, Laurent J, Robic MA, Christol C, et al
    Central obesity is associated with non-cirrhotic portal-vein thrombosis.
    J Hepatol. 2015 Aug 31. pii: S0168-8278(15)00596.
    PubMed     Text format     Abstract available


  114. LEI XF, Fu W, Kim-Kaneyama JR, Omoto T, et al
    Hic-5 deficiency attenuates the activation of hepatic stellate cells and liver fibrosis through upregulation of Smad7 in mice.
    J Hepatol. 2015 Aug 31. pii: S0168-8278(15)00598.
    PubMed     Text format     Abstract available


  115. KAMATH PS, Poterucha JJ, Ludwig J
    Primary Biliary Cirrhosis by Another Name is Still PBC.
    J Hepatol. 2015 Aug 19. pii: S0168-8278(15)00555.
    PubMed     Text format    


  116. GRANCINI V, Trombetta M, Lunati ME, Zimbalatti D, et al
    Contribution of beta-cell dysfunction and insulin resistance to cirrhosis-associated diabetes: role of severity of liver disease.
    J Hepatol. 2015 Aug 19. pii: S0168-8278(15)00553.
    PubMed     Text format     Abstract available


  117. BOSCH A, Dumortier J, Maucort-Boulch D, Scoazec JY, et al
    Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence.
    J Hepatol. 2015 Aug 14. pii: S0168-8278(15)00545.
    PubMed     Text format     Abstract available


    July 2015
  118. TODD STRAVITZ R, Reuben A, Mizrahi M, Lalazar G, et al
    Use of the Methacetin Breath Test to Classify the Risk of Cirrhotic Complications and Mortality in Patients Evaluated/Listed for Liver Transplantation.
    J Hepatol. 2015 Jul 25. pii: S0168-8278(15)00512.
    PubMed     Text format     Abstract available


  119. ZHENG Z, Zhang X, Wang J, Dandeka A, et al
    Exposure to Fine Airborne Particulate Matters Induces Hepatic Fibrosis in Murine Models.
    J Hepatol. 2015 Jul 25. pii: S0168-8278(15)00511.
    PubMed     Text format     Abstract available


  120. EL-SHAMY A, Eng FJ, Doyle EH, Klepper AL, et al
    A Cell Culture System for Distinguishing Hepatitis C Viruses with and without Liver Cancer-related Mutations in the Viral Core Gene.
    J Hepatol. 2015 Jul 25. pii: S0168-8278(15)00515.
    PubMed     Text format     Abstract available


  121. BERZIGOTTI A, Boyer TD, Castera L, de Franchis R, et al
    Reply to "Points to be considered when using transient elastography for diagnosis of portal hypertension according to the Baveno's VI consensus".
    J Hepatol. 2015 Jul 23. pii: S0168-8278(15)00475.
    PubMed     Text format    


  122. JEPSEN P, Watson H, Andersen PK, Vilstrup H, et al
    Diabetes as a risk factor for hepatic encephalopathy in cirrhosis patients.
    J Hepatol. 2015 Jul 20. pii: S0168-8278(15)00470.
    PubMed     Text format     Abstract available


  123. PERAZZO H, Fernandes FF, Castro Filho EC, Perez RM, et al
    Points to be considered when using transient elastography for diagnosis of portal hypertension according to the Baveno's VI consensus.
    J Hepatol. 2015 Jul 20. pii: S0168-8278(15)00468.
    PubMed     Text format    


  124. YANG YH, Chen WC, Tsan YT, Chen MJ, et al
    Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection.
    J Hepatol. 2015 Jul 18. pii: S0168-8278(15)00469.
    PubMed     Text format     Abstract available


  125. BERNARDI M, Moreau R, Angeli P, Schnabl B, et al
    Mechanisms of Decompensation and Organ Failure in Cirrhosis: From Peripheral arterial Vasodilation to Systemic Inflammation Hypothesis.
    J Hepatol. 2015 Jul 17. pii: S0168-8278(15)00466.
    PubMed     Text format     Abstract available


    June 2015
  126. FERENCI P, Kozbial K, Mandorfer M, Hofer H, et al
    HCV targeting of patients with cirrhosis.
    J Hepatol. 2015 Jun 19. pii: S0168-8278(15)00393.
    PubMed     Text format     Abstract available


  127. LAMPERTICO P, Invernizzi F, Vigano M, Loglio A, et al
    The long-term benefits of nucleos(t)ide analogs on esophageal varices in compensated HBV cirrhotics with no or small esophageal varices: A 12-year prospective cohort study.
    J Hepatol. 2015 Jun 19. pii: S0168-8278(15)00397.
    PubMed     Text format     Abstract available


  128. ALEXOPOULOU A, Vasilieva L, Agiasotelli D, Dourakis SP, et al
    Fungal Infections in patients with cirrhosis.
    J Hepatol. 2015 Jun 18. pii: S0168-8278(15)00396.
    PubMed     Text format    


  129. COUDROY R, Jamet A, Thille AW
    Is skin mottling a predictor of high mortality in non-selected patients with cirrhosis admitted to intensive care unit?
    J Hepatol. 2015 Jun 5. pii: S0168-8278(15)00383.
    PubMed     Text format    


    May 2015
  130. YADA A, Iimuro Y, Uyama N, Uda Y, et al
    Splenectomy attenuates murine liver fibrosis with hypersplenism stimulating hepatic accumulation of Ly-6C macrophages.
    J Hepatol. 2015 May 25. pii: S0168-8278(15)00337.
    PubMed     Text format     Abstract available


  131. FARRAR CT, DePeralta DK, Day H, Rietz TA, et al
    3D molecular MR imaging of liver fibrosis and response to rapamycin therapy in a bile duct ligation rat model.
    J Hepatol. 2015 May 25. pii: S0168-8278(15)00335.
    PubMed     Text format     Abstract available


  132. DA SILVA MIOZZO SA, Tovo CV, John JA, de Mattos AA, et al
    Proton pump inhibitor use and spontaneous bacterial peritonitis in cirrhosis: an undesirable association?
    J Hepatol. 2015 May 23. pii: S0168-8278(15)00334.
    PubMed     Text format    


  133. THEVENOT T, Monnet E, Di Martino V
    Reply to "Albumin infusion in cirrhotic patients with non-SBP infections: end of the story?"
    J Hepatol. 2015 May 18. pii: S0168-8278(15)00330.
    PubMed     Text format    


  134. MERLI M, Lucidi C, Lattanzi B, Riggio O, et al
    Albumin infusion in cirrhotic patients with infections other than Spontaneous Bacterial Peritonitis: end of the story?
    J Hepatol. 2015 May 16. pii: S0168-8278(15)00329.
    PubMed     Text format    


  135. MEHTA G, Dusheiko G
    Hepatitis C treatment and quality of life - you can't always get what you want, but you might get what you need.
    J Hepatol. 2015 May 13. pii: S0168-8278(15)00326.
    PubMed     Text format    


  136. ADAMS LA, Ratziu V
    Non-alcoholic fatty liver - perhaps not so benign.
    J Hepatol. 2015;62:1002-4.
    PubMed     Text format    


    April 2015
  137. MANNAERTS I, Leite SB, Verhulst S, Claerhout S, et al
    The Hippo pathway effector YAP controls mouse hepatic stellate cell activation.
    J Hepatol. 2015 Apr 20. pii: S0168-8278(15)00294.
    PubMed     Text format     Abstract available


  138. BARCENA C, Stefanovic M, Tutusaus A, Joannas L, et al
    Gas6/Axl pathway is activated in chronic liver disease and its targeting reduces fibrosis via hepatic stellate cell inactivation.
    J Hepatol. 2015 Apr 20. pii: S0168-8278(15)00296.
    PubMed     Text format     Abstract available


  139. BOURSIER J, de Ledinghen V, Poynard T, Guechot J, et al
    An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: the Liver-FibroSTARD standards.
    J Hepatol. 2015;62:807-15.
    PubMed     Text format     Abstract available


  140. TRAUTWEIN C, Friedman SL, Schuppan D, Pinzani M, et al
    Hepatic fibrosis: Concept to treatment.
    J Hepatol. 2015;62.
    PubMed     Text format     Abstract available


    March 2015
  141. LAURIDSEN MM, Bajaj JS
    Hepatic Encephalopathy Treatment and Driving: A Continental Divide.
    J Hepatol. 2015 Mar 18. pii: S0168-8278(15)00195.
    PubMed     Text format    


  142. YOUNOSSI ZM, Stepanova M, Afdhal N, Kowdley KV, et al
    Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir.
    J Hepatol. 2015 Mar 17. pii: S0168-8278(15)00192.
    PubMed     Text format     Abstract available


  143. WONG F, O'Leary JG, Reddy KR, Kamath PS, et al
    A cut-off serum creatinine value of 1.5 mg/dl for AKI--to be or not to be.
    J Hepatol. 2015;62:741-3.
    PubMed     Text format    


  144. FAGUNDES C, Barreto R, Rodriguez E, Graupera I, et al
    Reply to: "A cut-off serum creatinine value of 1.5 mg/dl for AKI--to be or not to be".
    J Hepatol. 2015;62:743-4.
    PubMed     Text format    


  145. PIANO S, Tonon M, Cavallin M, Morando F, et al
    Reply to: "A cut-off serum creatinine value of 1.5 mg/dl for AKI--to be or not to be".
    J Hepatol. 2015;62:744-6.
    PubMed     Text format    


  146. MEIER RP, Mahou R, Morel P, Meyer J, et al
    Microencapsulated human mesenchymal stem cells decrease liver fibrosis in mice.
    J Hepatol. 2015;62:634-41.
    PubMed     Text format     Abstract available


  147. PAWLAK M, Lefebvre P, Staels B
    Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease.
    J Hepatol. 2015;62:720-33.
    PubMed     Text format     Abstract available


  148. ALTROCK E, Sens C, Wuerfel C, Vasel M, et al
    Inhibition of fibronectin deposition improves experimental liver fibrosis.
    J Hepatol. 2015;62:625-33.
    PubMed     Text format     Abstract available


    February 2015
  149. SIMON TG, King LY, Chung RT
    Coagulation and fibrosis: a potential non-negligible target of statins in chronic hepatitis.
    J Hepatol. 2015 Feb 26. pii: S0168-8278(15)00138.
    PubMed     Text format    


  150. BITTO N, Salerno F, Tripodi A, Mura V, et al
    Coagulation and fibrosis: a potential non-negligible target of statins in chronic hepatitis.
    J Hepatol. 2015 Feb 25. pii: S0168-8278(15)00137.
    PubMed     Text format    


  151. KOCABAYOGLU P, Lade A, Lee YA, Dragomir AC, et al
    beta-PDGF Receptor Expressed by Hepatic Stellate Cells Regulates Fibrosis in Murine Liver Injury, but Not Carcinogenesis.
    J Hepatol. 2015 Feb 9. pii: S0168-8278(15)00073.
    PubMed     Text format     Abstract available


    January 2015
  152. NEGRO F
    Are statins a remedy for all seasons?
    J Hepatol. 2015;62:8-10.
    PubMed     Text format    


  153. FORNER A, Vilana R, Bianchi L, Rodriguez-Lope C, et al
    Lack of arterial hypervascularity at contrast-enhanced ultrasound should not define the priority for diagnostic work-up of nodules <2 cm.
    J Hepatol. 2015;62:150-5.
    PubMed     Text format     Abstract available


  154. CUBERO FJ, Zhao G, Nevzorova YA, Hatting M, et al
    Haematopoietic cell-derived Jnk1 is crucial for chronic inflammation and carcinogenesis in an experimental model of liver injury.
    J Hepatol. 2015;62:140-9.
    PubMed     Text format     Abstract available


    December 2014
  155. MORGAN TR
    Prognosis of treated severe alcoholic hepatitis in patients with gastrointestinal bleeding.
    J Hepatol. 2014 Dec 24. pii: S0168-8278(14)00942.
    PubMed     Text format    


  156. KLUGER MD, Salceda JA, Laurent A, Tayar C, et al
    Liver Resection For Hepatocellular Carcinoma in 313 Western Patients: Tumor Biology and Underlying Liver Rather than Tumor Size Drive Prognosis.
    J Hepatol. 2014 Dec 18. pii: S0168-8278(14)00939.
    PubMed     Text format     Abstract available


  157. MORRISON MC, Liang W, Mulder P, Verschuren L, et al
    Mirtoselect, an anthocyanin-rich bilberry extract, attenuates non-alcoholic steatohepatitis and associated fibrosis in ApoE *3Leiden mice.
    J Hepatol. 2014 Dec 13. pii: S0168-8278(14)00929.
    PubMed     Text format     Abstract available


    November 2014
  158. MCPHERSON S, Hardy T, Henderson E, Burt AD, et al
    Evidence of NAFLD Progression from Steatosis to Fibrosing-Steatohepatitis Using Paired Biopsies: Implications for Prognosis & Clinical Management.
    J Hepatol. 2014 Nov 29. pii: S0168-8278(14)00883.
    PubMed     Text format     Abstract available


  159. KIM GA, Lee HC, Kim MJ, Ha Y, et al
    Incidence of Hepatocellular Carcinoma after HBsAg Seroclearance in Chronic Hepatitis B Patients: a Need for Surveillance.
    J Hepatol. 2014 Nov 28. pii: S0168-8278(14)00880.
    PubMed     Text format     Abstract available


  160. LUNOVA M, Nahon P, Trautwein C, Strnad P, et al
    Hepcidin in chronic liver disease and hepatocellular carcinoma: the plot thickens.
    J Hepatol. 2014 Nov 21. pii: S0168-8278(14)00851.
    PubMed     Text format    


  161. SOMBETZKI M, Fuchs CD, Fickert P, Oesterreicher C, et al
    24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis.
    J Hepatol. 2014 Nov 21. pii: S0168-8278(14)00865.
    PubMed     Text format     Abstract available


  162. RUDLER M, Mouri S, Charlotte F, Lebray P, et al
    Prognosis of treated severe alcoholic hepatitis in patients with gastrointestinal bleeding.
    J Hepatol. 2014 Nov 11. pii: S0168-8278(14)00818.
    PubMed     Text format     Abstract available


  163. WESTBROOK RH, Dusheiko G
    Natural history of hepatitis C.
    J Hepatol. 2014;61.
    PubMed     Text format     Abstract available


    October 2014
  164. HUANG CF, Dai CY, Yeh ML, Huang CI, et al
    Association of diabetes and PNPLA3 genetic variants with disease severity of patients with chronic hepatitis C virus infection.
    J Hepatol. 2014 Oct 20. pii: S0168-8278(14)00740.
    PubMed     Text format     Abstract available


  165. GUO R, Xu X, Babcock SA, Zhang Y, et al
    Aldehyde Dehydrogenase-2 (ALDH2) Ameliorates Chronic Alcohol Ingestion-Induced Hepatic Steatosis and Inflammation: Role of Autophagy.
    J Hepatol. 2014 Oct 20. pii: S0168-8278(14)00738.
    PubMed     Text format     Abstract available


  166. SECKLEHNER J, Richardson CA
    The reporting of animal welfare details in liver research: A review of studies describing bile duct ligation in mice (2011-2013).
    J Hepatol. 2014 Oct 1. pii: S0168-8278(14)00720.
    PubMed     Text format    


    September 2014
  167. SHOUVAL D, Friedman SL
    Focusing on the Past, Present and Future of Hepatology.
    J Hepatol. 2014 Sep 4. pii: S0168-8278(14)00627.
    PubMed     Text format    


    August 2014
  168. SIMON TG, King LY, Zheng H, Chung RT, et al
    Statin Use is Associated with a Reduced Risk of Fibrosis Progression in Chronic Hepatitis C.
    J Hepatol. 2014 Aug 15. pii: S0168-8278(14)00552.
    PubMed     Text format     Abstract available


  169. CHEN L, Li J, Zhang J, Dai C, et al
    S100A4 promotes liver fibrosis via activation of hepatic stellate cells.
    J Hepatol. 2014 Aug 8. pii: S0168-8278(14)00541.
    PubMed     Text format     Abstract available


  170. TIAN W, Hao C, Fan Z, Weng X, et al
    Myocardin related transcription factor A programs epigenetic activation of hepatic stellate cells.
    J Hepatol. 2014 Aug 7. pii: S0168-8278(14)00533.
    PubMed     Text format     Abstract available


    July 2014
  171. POYNARD T, Vergniol J, Ngo Y, Foucher J, et al
    Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest) and elastography (FibroScan).
    J Hepatol. 2014 Jul 9. pii: S0168-8278(14)00457.
    PubMed     Text format     Abstract available


  172. ZHANG L, Schuppan D
    Traditional Chinese Medicine (TCM) for fibrotic liver disease: hope and hype.
    J Hepatol. 2014;61:166-8.
    PubMed     Text format    


  173. TRIPODI A, Fracanzani AL, Primignani M, Chantarangkul V, et al
    Procoagulant imbalance in patients with non-alcoholic fatty liver disease.
    J Hepatol. 2014;61:148-54.
    PubMed     Text format     Abstract available


  174. HUANG Y, de Boer WB, Adams LA, MacQuillan G, et al
    Image analysis of liver biopsy samples measures fibrosis and predicts clinical outcome.
    J Hepatol. 2014;61:22-7.
    PubMed     Text format     Abstract available


  175. CHIAVAROLI L, Ha V, Kendall CW, Sievenpiper JL, et al
    Is industrial fructose just a marker of an unhealthy dietary pattern?
    J Hepatol. 2014;61:172-3.
    PubMed     Text format    


  176. PETTA S, Marchesini G, Craxi A
    Reply to: "is industrial fructose just a marker of an unhealthy dietary pattern?".
    J Hepatol. 2014;61:173-5.
    PubMed     Text format    


    June 2014
  177. NISCHALKE HD, Lutz P, Kramer B, Sohne J, et al
    A common polymorphism in the NCAN gene is associated with hepatocellular carcinoma in alcoholic liver disease.
    J Hepatol. 2014 Jun 16. pii: S0168-8278(14)00401.
    PubMed     Text format     Abstract available


  178. COLOMBO M, Strasser SI, Moreno C, Ferreira PA, et al
    Sustained Virological Response with Telaprevir in 1078 Patients With Advanced Hepatitis C: The International Telaprevir Access Program.
    J Hepatol. 2014 Jun 16. pii: S0168-8278(14)00400.
    PubMed     Text format     Abstract available


    May 2014
  179. PINYOL R, Tovar V, Llovet JM
    TERT promoter mutations: Gatekeeper and driver of hepatocellular carcinoma.
    J Hepatol. 2014 May 22. pii: S0168-8278(14)00375.
    PubMed     Text format    


  180. KROY DC, Schumacher F, Ramadori P, Hatting M, et al
    Hepatocyte specific deletion of c-Met leads to the development of severe non-alcoholic-steatohepatitis in mice.
    J Hepatol. 2014 May 15. pii: S0168-8278(14)00360.
    PubMed     Text format     Abstract available


  181. HARRIS RJ, Thomas B, Griffiths J, Costella A, et al
    Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: modelling the predicted impact of treatment under different scenarios.
    J Hepatol. 2014 May 10. pii: S0168-8278(14)00318.
    PubMed     Text format     Abstract available


  182. NI HM, Woolbright BL, Williams J, Copple B, et al
    Nrf2 Promotes the Development of Fibrosis and Tumorigenesis in Mice with Defective Hepatic Autophagy.
    J Hepatol. 2014 May 7. pii: S0168-8278(14)00306.
    PubMed     Text format     Abstract available


  183. MACALUSO FS, Maida M, Camma C, Cabibbo G, et al
    Steatosis Affects the Performance of Liver Stiffness Measurement for Fibrosis Assessment in Patients with Genotype 1 Chronic Hepatitis C.
    J Hepatol. 2014 May 7. pii: S0168-8278(14)00308.
    PubMed     Text format     Abstract available


  184. FRIEDMAN SL
    Replacing a crystal ball with a calculator in predicting liver disease outcomes.
    J Hepatol. 2014;60:905-6.
    PubMed     Text format    


  185. MCPHERSON S, Henderson E, Burt AD, Day CP, et al
    Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease.
    J Hepatol. 2014;60:1055-62.
    PubMed     Text format     Abstract available


  186. TACKE F, Zimmermann HW
    Macrophage heterogeneity in liver injury and fibrosis.
    J Hepatol. 2014;60:1090-6.
    PubMed     Text format     Abstract available


  187. ASRANI SK, Talwalkar JA, Kamath PS, Shah VH, et al
    Role of magnetic resonance elastography in compensated and decompensated liver disease.
    J Hepatol. 2014;60:934-9.
    PubMed     Text format     Abstract available


    April 2014
  188. MAAN R, van der Meer AJ, Hansen BE, Feld JJ, et al
    Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis.
    J Hepatol. 2014 Apr 26. pii: S0168-8278(14)00284.
    PubMed     Text format     Abstract available


  189. HEZODE C, Fontaine H, Barthe Y, Carrat F, et al
    Reply to: "From the CUPIC study: great times are not coming(?)".
    J Hepatol. 2014;60:900-1.
    PubMed     Text format    


  190. SCHMIDT-MARTIN D, Houlihan D, McCormick A
    From the CUPIC study: great times are not coming(?).
    J Hepatol. 2014;60:899-900.
    PubMed     Text format    


  191. SHAH HA, Azam Z, Rauf J, Abid S, et al
    Carvedilol vs. esophageal variceal band ligation in the primary prophylaxis of variceal hemorrhage: a multicentre randomized controlled trial.
    J Hepatol. 2014;60:757-64.
    PubMed     Text format     Abstract available


  192. MARINO Z, Mensa L, Crespo G, Miquel R, et al
    Early periportal sinusoidal fibrosis is an accurate marker of accelerated HCV recurrence after liver transplantation.
    J Hepatol. 2014 Apr 1. pii: S0168-8278(14)00210.
    PubMed     Text format     Abstract available


    March 2014
  193. TOMITA K, Teratani T, Suzuki T, Shimizu M, et al
    Acyl-CoA:cholesterol acyltransferase 1 mediates liver fibrosis by regulating free cholesterol accumulation in hepatic stellate cells.
    J Hepatol. 2014 Mar 18. pii: S0168-8278(14)00164.
    PubMed     Text format     Abstract available


  194. DEUFFIC-BURBAN S, Schwarzinger M, Obach D, Mallet V, et al
    Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 12188).
    J Hepatol. 2014 Mar 17. pii: S0168-8278(14)00155.
    PubMed     Text format     Abstract available


  195. LEROY V, Sturm N, Faure P, Trocme C, et al
    Prospective evaluation of Fibrotest, Fibrometer and Hepascore for staging liver fibrosis in chronic hepatitis B: Comparison with hepatitis C.
    J Hepatol. 2014 Mar 11. pii: S0168-8278(14)00137.
    PubMed     Text format     Abstract available


    February 2014
  196. XU S, Wang Y, Tai DC, Wang S, et al
    qFibrosis: A fully-quantitative innovative method incorporating histological features to facilitate accurate fibrosis scoring in animal model and chronic hepatitis B patients.
    J Hepatol. 2014 Feb 25. pii: S0168-8278(14)00121.
    PubMed     Text format     Abstract available


    January 2014
  197. MANINI MA, Sangiovanni A, Fornari F, Piscaglia F, et al
    Clinical and Economical Impact of 2010 AASLD Guidelines for the Diagnosis of Hepatocellular Carcinoma.
    J Hepatol. 2014 Jan 21. pii: S0168-8278(14)00049.
    PubMed     Text format     Abstract available


    December 2013
  198. FAGIUOLI S, Colli A, Bruno R, Craxi A, et al
    Management of infections pre- and post-liver transplantation: Report of a AISF Consensus Conference.
    J Hepatol. 2013 Dec 30. pii: S0168-8278(13)00890.
    PubMed     Text format     Abstract available


    November 2013
  199. POYNARD T, Vergniol J, Ngo Y, Foucher J, et al
    Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest) and transient elastography (FibroScan).
    J Hepatol. 2013 Nov 26. pii: S0168-8278(13)00817.
    PubMed     Text format     Abstract available


  200. SHOEB D, Dearden J, Weatherall A, Bargery C, et al
    Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: final results from the STEPS trial.
    J Hepatol. 2013 Nov 26. pii: S0168-8278(13)00812.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Cirrhosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: